Get in Touch

Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics

Miami, Florida – March 27, 2020 - Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), announced today that Dr. Mark Braunstein, DO, ABPN has been appointed to its Medical Advisory Board as its Chief Psychedelic Officer. Dr. Braunstein will join other members of the Medical Advisory Board evaluating various technologies, acquisitions, investments, joint ventures, and all other business related to psychedelics. 

Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has maintained a private psychiatric practice in Durango, Colorado for the past 17 years and works with students and families at the world-renowned Open Sky Wilderness Therapy facility. 

"Our goal is to build Ehave into a leader in the field of Psychedelic Medicine. In order to do so, it is imperative we bring together a world-class Advisory Board to advise management on the scientific merit and medical capabilities of our future acquisitions, our data platform, and our global ecosystem that accelerates psychedelic innovation," said Ehave CEO, Ben Kaplan. "After 17 years of practice, Dr. Braunstein has treated more than 10,000 patients with psychedelic therapy and is well known for involving clients in their own treatment process, developing a therapeutic alliance with treatment-resistant youth. He brings an abundance of real-world experience in both mental health and psychedelic medicine to his role of Chief Psychedelic Officer of Ehave."

Dr. Mark Braunstein added, "My goal is to help Ehave become a leader in the ethical use of psychedelics, as well as bringing them access to my global contacts in the industry."

Dr. Braunstein received a BS in Mathematics from the University of Florida and earned his medical degree at Nova Southeastern University College of Osteopathic Medicine in 1997. He completed his residency in General Psychiatry at the University of New Mexico and a fellowship in Child and Adolescent Psychiatry at the Maine Medical Center in Portland, Maine. Dr. Braunstein is board certified in General Psychiatry and specializes in psychedelic psychiatry, which entails treating psychiatric disorders, adjusting dosages and formulations, and using evidence-based psychedelics science in prescribing psychedelics as a medical treatment. He has been an activist for 20 years advocating for the ethical and safe use of psychedelics. Dr. Braunstein brings a team with 40 years of clinical experience, which includes clinical training and raising awareness of the responsible use of psychedelics. Patients of Dr. Braunstein often enter treatment with him over-medicated, and most leave on fewer and sometimes no prescriptions at all. 

The Advisory Board will provide non-binding and informed guidance to the Ehave Board of Directors, as well as relevant information for superior corporate governance. 

Ehave is developing software-based solutions for the digital assessment and remediation of the most common mental health disorders faced by children and adolescents. With pilot studies underway, Ehave is launching several digital applications under its brand for the assessment and remediation of ADHD, with a specific focus on the use of psychedelics to treat various mental disorders. Ehave recently launched its Mycotopia Therapy subsidiary to provide an ecosystem of a worldwide network of clinics and wellness centers focused on natural and digital therapies to address mental wellness issues.

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.


Key Takeaways
  • Dr. Mark Braunstein, DO, ABPN has been appointed its Medical Advisory Board as its Chief Psychedelic Officer. Dr. Braunstein will join other members of the Medical Advisory Board evaluating various technologies, acquisitions, investments, joint ventures, and all other business related to psychedelics.
  • Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance.
  • Ehave is developing software-based solutions for the digital assessment and remediation of the most common mental health disorders faced by children and adolescents.
Media Gallery
Quotes
"My goal is to help Ehave become a leader in the ethical use of psychedelics, as well as bringing them access to my global contacts in the industry."
Dr. BraunsteinChief Psychedelic Officer
Contacts
Gabe Rodriguez
ir@ehave.com
(623) 261-9046
Investor